Dialgin

Quick links to important sections

Dialgin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dialgin

What is Dialgin? Definition and Active Composition

Property Description
Active ingredient Sodium Metamizole (Metamizole Sodium, Dipyrone)
Form Tablets, oral drops, solution for injection, suppositories
Pharmacological class Non-opioid analgesic, Antipyretic, Pyrazolone derivative
General purpose Pain relief and fever reduction
Origin Synthetic compound

Dialgin is a trade name for a potent, synthetic medicinal entity whose active ingredient is Sodium Metamizole, also known as Metamizole Sodium or Dipyrone. Chemically, it is classified as a pyrazolone derivative, a group of compounds noted for high efficacy in acute pain management. This formulation is typically a single active ingredient product, focusing the therapeutic effects entirely on the actions of Metamizole. The active substance’s chemical structure is clinically recognized for providing a rapid onset of action, which makes it a valuable option when quick symptomatic control is necessary.

Pharmacological Class and Purpose

Dialgin is definitively classified as a powerful non-opioid analgesic and a reliable antipyretic. Its general therapeutic purpose is to provide substantial, rapid relief from both moderate to severe pain and elevated body temperature (fever). Unlike many other common over-the-counter pain medications, Sodium Metamizole also possesses a distinct spasmolytic effect. The inclusion of this spasmolytic property means the medication can aid in relieving discomfort associated with smooth muscle cramping, often encountered in scenarios like kidney or biliary colic.

Available Forms and Administration Types

Sodium Metamizole is manufactured in multiple dosage form(s) to ensure flexibility in its clinical application. These preparations include oral formulations such as tablets and oral drops, as well as rectal formulations (suppositories), and sterile solution for injection for parenteral use. The variety of forms ensures that Dialgin can be administered through different route(s) of administration—oral, rectal, or injection—allowing healthcare providers to select the method best suited to the patient’s acute needs and the desired speed of therapeutic onset.

What side effects are possible with Dialgin?

Possible side effects and safety information

The safety profile of Metamizole Sodium (Dialgin), as outlined in regulatory documents, centers on two major categories of concern: hematological disorders and severe hypersensitivity reactions.

Adverse Reaction Classification

Classification Examples of Officially Listed Adverse Reactions
Common Nausea, vomiting, headache, somnolence, vertigo.
Rare Agranulocytosis, leukopenia, urticaria, non-allergic hypotension.
Very Rare Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), acute renal failure.

Serious adverse reactions, though rare, include Agranulocytosis—a sudden, life-threatening reduction in white blood cells—and systemic reactions such as Anaphylactic Shock and Acute Liver Failure. Regulatory documents specify that Agranulocytosis can occur at any time during treatment and its occurrence is not dose-dependent.

Safety Considerations and Restrictions

The official labeling defines specific constraints for use. The medication is contraindicated in infants below 3 months of age or 5 kg and during the third trimester of pregnancy. It must not be used in individuals with a history of agranulocytosis from Metamizole or related drugs, or in those with pre-existing bone marrow disorders. High-level safety notes highlight that the risk of non-allergic hypotension is related to the speed of intravenous administration. Additionally, a harmless, reddish discoloration of the urine may be noted due to a metabolic product.

Overdose and Emergency Response

Overdose and when to seek help

In the event of suspected over-ingestion of Dialgin (Metamizole Sodium), immediate medical attention is required, as mandated by regulatory authorities. The official regulatory profile indicates that the manifestations of acute systemic intoxication may include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain. Central nervous system effects are also documented, encompassing dizziness, headache, and a loss of coordination (ataxia).


Severe Outcomes and Monitoring Requirements

Symptoms of systemic poisoning may not appear immediately, as effects can be delayed several hours post-ingestion. The most severe potential outcomes documented are circulatory compromise, including severe drops in blood pressure (hypotension) and a state of shock. Due to the risk of delayed systemic effects, regulatory documentation mandates that patients must undergo medical observation for at least 48 hours.

Management and Antidote Status

Since no specific antidote is known for Metamizole overdose, the required management approach is strictly symptomatic and supportive treatment. In cases of recent ingestion, procedures such as gastrointestinal decontamination using activated charcoal may be considered. Any suspected overdose requires calling emergency services immediately.

Therapeutic Uses of Dialgin

Quick Facts

  • Supports management of pain and inflammation.
  • Utilized in conditions such as rheumatoid arthritis and osteoarthritis.
  • A therapeutic option for various muscle and joint conditions.

Dialgin is a prescription medication used in the management of specific physical discomfort and inflammatory processes. It is utilized to provide relief from pain and address inflammatory symptoms associated with conditions that affect the joints and muscles.

Therapeutic applications include the supportive care of chronic conditions such as rheumatoid arthritis, a disease characterized by joint inflammation, and osteoarthritis, which involves joint cartilage degeneration. It is also an established component in the treatment protocol for ankylosing spondylitis, which primarily affects the spine.

Furthermore, Dialgin is a therapeutic option for managing acute inflammatory responses and pain stemming from various injuries, including sprains and strains, as well as tendonitis. It is one of the available interventions to address pain and inflammation following certain surgical procedures.

Eligibility and Restrictions for Use

Who can and cannot use Dialgin? — Official Regulatory Information

This medicine is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks in adults aged 18 years or older. Its use is governed by specific regulatory eligibility rules.

Eligibility Status Defined Populations
Contraindicated (MUST NOT USE) Patients with a known hypersensitivity to the drug or a history of allergic reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs. Also prohibited in the setting of coronary artery bypass graft (CABG) surgery.
Avoid Use or Restricted Pregnancy at or after 30 weeks gestation (risk of fetal heart/kidney problems). Severe heart failure or advanced renal disease (use only if benefits clearly outweigh risks). Use is limited between 20 and 30 weeks of pregnancy.
Use Not Established Pediatric patients (under 18 years of age) and for the acute treatment of cluster headache.

Regulatory documents stipulate that older patients (geriatric use) are at increased risk for certain adverse events, and caution is required. Patients with conditions like a history of gastrointestinal bleeding or peptic ulcer disease are at higher risk for serious complications. This medicine is strictly for the acute treatment of migraine and is not indicated for prophylactic therapy.

What should I know about interactions with other medicines?

Dialgin Interactions with other medicines and products

Dialgin (Metamizole Sodium) is officially recognized as having several significant interactions that fall into both pharmacokinetic (exposure-modifying) and pharmacodynamic (effect-altering) categories, as documented in regulatory prescribing information.


Pharmacokinetic Interactions

Metamizole is a moderate to strong inducer of multiple CYP enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction activity leads to the enhanced breakdown and significantly reduced plasma concentrations of co-administered drugs that are substrates of these enzymes, such as Ciclosporin, Efavirenz, and Bupropion. This reduction in drug exposure may compromise the efficacy of the co-administered medication.

Metamizole is also documented as a weak inhibitor of CYP1A2, which can potentially lead to increased plasma concentrations for drugs metabolized by that enzyme.


Pharmacodynamic Interactions

Interacting Medicine Official Regulatory Finding
Acetylsalicylic Acid (Aspirin) Antagonism that reduces the antiplatelet effect of Aspirin.
Methotrexate Co-administration is associated with an additive risk for haematologic toxicity.
Chlorpromazine Co-administration may result in additive hypothermia.

Timing Requirements

Official labeling mandates a separation of administration timing (delay) when Metamizole is used by patients taking low-dose Aspirin for vascular protection.

Mechanism of Action

Modulating the Heart's Contraction Force

Dialgin acts by inhibiting the Sodium-Potassium Pump ( Na^+/ K^+-ATPase) in heart cells, an enzyme that mediates the transport of sodium and potassium ions. This molecular effect initiates a cascade that alters the electrochemical gradient, resulting in an increase of internal calcium ions in the myocyte. This leads directly to an increased force of contraction of the heart muscle (positive inotropic effect).


Influencing Cardiac Electrical Rhythm and Rate

The mechanism also involves the enhancement of vagal nerve activity, a division of the nervous system that innervates the heart. This action slows the speed at which electrical signals are conducted through the atrioventricular (AV) node, the primary conduction pathway between the atria and the ventricles. This leads to a reduction in the conduction velocity, resulting in a slower heart rate.

Dosage and Administration Information

Dialgin, which contains the active ingredient Metamizole Sodium, is administered via multiple pathways, including oral (tablets, drops), intravenous (IV), intramuscular (IM), and rectal (suppositories) routes.

Dosing and Frequency

Administration is generally patterned for as-needed use, with the general goal being to select the lowest effective dose for the shortest duration required. For adults (aged 15 years and older), a maximum single oral dose is set at 1,000 mg, taken up to four times daily. This establishes a maximum daily dose of 4,000 mg for oral forms, with doses typically separated by 6 to 8 hours. If the medicine is administered parenterally, the total daily dose must not exceed 5,000 mg. Dosing for the pediatric population is strictly weight-based, typically ranging from 8 mg to 16 mg per kilogram of body weight as a single dose.

Administration Requirements

Specific procedural requirements govern the use of the injection solution. For IV administration, the solution is warmed to body temperature and administered very slowly—not exceeding 1 mL/minute—to mitigate risk. Furthermore, IV injection is given with the patient lying down. The injectable solution may be diluted with standard IV fluids such as 5% glucose solution or 0.9% saline, and is administered immediately after preparation. For patients with renal or hepatic impairment, standard guidelines advise against the use of multiple high doses.

Recent Clinical Evidence

Research evidence / Overview of studies for Dialgin (Metamizole)

Evidence for use in Acute Pain Management (Post-Surgical and Colic)

Metamizole was studied for use in conditions related to acute pain, such as the discomfort experienced immediately following surgery or during episodes of acute colic (severe, fluctuating pain often associated with kidney or bile duct issues). Short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews monitored outcomes related to physical discomfort, examining the intensity of pain and the measured need for additional rescue pain medication in adult populations.

Studies monitored changes in patient-reported outcomes describing perceived discomfort. Findings from these studies reported patterns of change in pain scores during the immediate 24 to 48 hour post-operative period. The research structure for both acute pain types is defined by high-quality study designs (RCTs) for short-term outcomes. However, follow-up durations were limited, meaning that data tracking patient comfort and functioning beyond the first two weeks is not fully established.

Evidence for use in Fever Reduction (Antipyretic Use)

Metamizole was studied for use in contexts related to elevated body temperature in research examining temporary physiological imbalance, specifically in both febrile adults and children whose symptoms were refractory (unresponsive) to other common treatments. Studies monitored outcomes related to systemic or functional imbalance, such as the absolute degree of change in body temperature and the time it takes for any change to be measured.

Studies report how symptoms evolved in the observed populations, indicating patterns where Metamizole administration was associated with measured changes in peak body temperature. Research highlights changes measured during the study period, often reporting that the measured change in temperature was observed to have a rapid onset and a sustained pattern over a specific number of hours. Comparative evidence is sometimes uncertain due to the variability in defining "refractory" fever across the studies.

What is Still Uncertain About the Research Evidence

Despite the use of Metamizole in several acute settings, the evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking in some areas, meaning direct, head-to-head trials against all modern alternatives are not consistently available across all indications. Findings were mixed in some systematic reviews, particularly when assessing the consistency of findings across different geographical regions or patient populations. Furthermore, a recurring limitation noted is that sample sizes were modest in some of the included trials, and the evidence quality varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Dialgin (FAQ)

Q: Is Dialgin a pain reliever or an anti-inflammatory drug?

Official documents describe Dialgin as primarily having analgesic (pain-relieving) and antipyretic (fever-reducing) effects. While it is classified as an atypical Non-Steroidal Anti-Inflammatory Drug (NSAID), its anti-inflammatory action is described in official sources as being significantly weaker than its central pain-relieving effects.


Q: Why is Dialgin sometimes preferred over other similar medications?

Official information notes that this medicine possesses a distinct spasmolytic (cramp-relieving) effect. This property is noted for potential use in conditions like colic. Furthermore, its rapid onset of action is a feature that may lead to its selection for specific acute pain scenarios, according to regulatory-backed studies.


Q: Is it normal to feel a slight headache when starting Dialgin?

According to official product information, headache is listed as a common adverse reaction. Its inclusion in the common category on regulatory labels means it is among the effects more frequently observed in clinical data.


Q: Does Dialgin require a prescription in most places?

The regulatory status of this medicine is not uniform globally and varies significantly by country. While it is classified as Prescription-Only in many regions, it may be available as an Over-The-Counter (OTC) product in others, depending on local government regulations.


Q: Are there different strengths or forms of Dialgin available?

Yes, official documents confirm that the medicine is manufactured in multiple dosage forms. These preparations include oral tablets and drops, a sterile solution for injection, and rectal suppositories.


Q: Can women who are pregnant or breastfeeding use Dialgin?

Regulatory bodies advise against the medicine's use during the third trimester of pregnancy due to potential risks to the fetus. For breastfeeding, official documents advise against repeated use, and breastmilk should be discarded for a 48-hour period following a single dose.


Q: Can teenagers or children use Dialgin?

Official pediatric weight-based dosing is available for children over 3 months. However, regulatory labeling may have use restricted to when other suitable treatments have been exhausted, particularly in patients under 18 years old.


Q: What does the official product information say about long-term use of Dialgin?

Regulatory recommendations describe the need to select the lowest effective dose for the shortest duration considered appropriate. The available research evidence primarily focuses on short-term trials, and long-term safety data is not fully established.


Q: What should I do if a side effect of Dialgin doesn't go away?

Official guidance associated with potential severe adverse reactions outlines that pausing treatment may be required if a persistent or concerning symptom is suspected. Official guidance emphasizes the need for consultation with a healthcare professional for evaluation.


Q: What is the risk of serious side effects with Dialgin?

Official documents highlight that rare, but serious, adverse reactions include Agranulocytosis (a severe drop in white blood cells) and Anaphylactic Shock. Regulatory labeling notes that Agranulocytosis can occur at any time during treatment and its occurrence is not dependent on the dose amount.


Q: Does Dialgin have an effect on mental clarity?

Official labeling lists somnolence (drowsiness) and vertigo (dizziness) as common side effects. These reactions have the potential to affect concentration and mental clarity.


Q: Can I take Dialgin if I have high blood pressure?

Regulatory information indicates the medicine can interfere with the action of certain antihypertensive drugs, which are used to control high blood pressure. This potential interference is described as possibly leading to less effective blood pressure management.


Q: Does taking Dialgin affect laboratory blood test results?

Official product information notes that a harmless, reddish discoloration of the urine may be noted due to a metabolic product. Additionally, if certain serious adverse reactions are suspected, regulatory guidance requires the monitoring of your blood cell count and/or liver enzymes.


Q: What happens if I miss taking a dose of Dialgin?

Official patient information leaflets for this type of medicine generally advise that if a dose is missed, the general approach is to skip the missed dose if the next scheduled time is near. It is noted that a double dose should not be taken to try and compensate for the missed one.


Q: Is Dialgin considered a controlled substance?

The medicine is classified as a non-opioid analgesic and is not typically considered a Controlled Substance under international agreements. However, its sale and use are banned or highly restricted in some countries due to concerns related to certain rare side effects.


Q: How does Dialgin work differently from aspirin?

Regulatory-backed studies indicate that while both medicines relieve pain, Dialgin's primary analgesic effect is thought to involve the inhibition of central cyclooxygenase-3 (COX-3) in the brain and spinal cord. Aspirin, in contrast, primarily acts by inhibiting peripheral COX-1.


Q: Does taking Dialgin affect my ability to drive or operate machinery?

Official documents include warnings related to the use of machinery or driving. This is due to the potential for side effects such as somnolence (drowsiness), vertigo (dizziness), and hypotension (low blood pressure) which could impair reaction time.


Q: Have there been any major changes to the safety information for Dialgin recently?

Yes, regulatory documents confirm that periodic reviews by agencies like the European Medicines Agency (EMA) have resulted in updates. For example, recent changes have occurred concerning restrictions during pregnancy and breastfeeding.


Q: Why do some people need to avoid Dialgin if they have kidney problems?

Official warnings are related to the potential risk of Acute Kidney Injury (AKI), particularly when the medicine is used with certain other medications or in patients with existing kidney impairment. This caution is mentioned because of the risk of negatively impacting kidney function.


Q: Are the side effects of Dialgin more severe in certain patient groups?

Official documents note that older patients are noted to be at an increased risk for certain adverse events. Caution is also advised, and may be associated with the need for caution if the patient has pre-existing liver or kidney impairment.


Q: Is there a specific time of day recommended for taking Dialgin?

Official instructions for the use of this medicine focus on the necessary interval between doses (typically 6–8 hours) and not exceeding the maximum daily dose. They do not mandate a specific time of day (e.g., morning or evening) for the initial dose.


Q: Is Dialgin used for conditions other than those listed in its official labeling?

The official labeling lists the specific uses approved by regulatory agencies, such as for pain and fever. Off-label use is a term for when the medicine is prescribed for a purpose, population, or method that is not included in that official, approved labeling.


Q: What are the key findings from the clinical trials of Dialgin?

Studies examined for regulatory approval reported evidence of changes in pain scores in the immediate post-operative period and measured changes in peak body temperature when the medicine was administered for fever reduction.


Q: How long does the effect of one dose of Dialgin typically last?

While the exact duration varies between individuals, official dosing recommendations generally suggest a maximum interval between doses of 6 to 8 hours. This interval reflects the expected therapeutic duration of the medicine’s effects.


Q: What is the difference between Dialgin's main use and an off-label use?

The main use is the specific purpose, patient group, and method that the medicine is officially approved for by a regulatory agency. An off-label use is any other way the medicine is prescribed that falls outside of that official, approved labeling.


Q: What is the difference between Dialgin and a common antibiotic?

Dialgin is classified as a non-opioid analgesic and antipyretic, meaning its general purpose is to relieve pain and fever. An antibiotic belongs to a different pharmacological class used specifically to kill or slow the growth of bacteria.


Q: Does taking Dialgin affect my blood pressure reading?

Official warnings list non-allergic hypotension (low blood pressure) as a rare side effect, particularly when the solution for injection is administered too rapidly. This effect can impact blood pressure readings.


Q: Is Dialgin known to cause allergic reactions?

Yes, official documents confirm that the medicine is associated with a risk of hypersensitivity reactions. These can range from skin reactions like hives (urticaria) to severe, life-threatening reactions such as Anaphylactic Shock and Stevens-Johnson Syndrome (SJS).


Q: How does Dialgin work?

The pain-relieving and fever-reducing mechanism is thought to involve the inhibition of central cyclooxygenase-3 (COX-3) located in the central nervous system. This process also involves the activation of the opioidergic and cannabinoid systems in the central nervous system.


Q: Is Dialgin safe to use for people over 65 years old?

Official documents do not use the term 'safe' but state that older patients are noted to be at an increased risk for certain adverse events. Therefore, extra caution is required during use, and a lower dose may be necessary if kidney or liver function is reduced.

How should Dialgin be stored and disposed of?

How to Store and Dispose of Dialgin?

Dialgin (Metamizole Sodium) must be stored and handled according to its official regulatory labeling to ensure product integrity and safety.


Storage Requirements

  • Temperature and Protection: Store the product at or not above 25 C (77 F). It must be protected from light and moisture. Do not store in the freezer.
  • Packaging and Child Safety: Keep the medicine in its original package. It must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired product must be conducted according to local requirements. The medicine must not be discarded via wastewater or household waste unless specifically authorized by a local drug take-back program. Specific liquid formulations may have a limited shelf-life after first opening the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dialgin found in:

A-Z Index: